𝔖 Bobbio Scriptorium
✦   LIBER   ✦

PD31-03 STATIN USE AND SURVIVAL AFTER PROSTATE CANCER DIAGNOSIS IN THE FINNISH PROSTATE CANCER SCREENING TRIAL

✍ Scribed by Murtola, Teemu; Määttänen, Liisa; Taari, Kimmo; Tammela, Teuvo; Auvinen, Anssi

Book ID
122203985
Publisher
Lippincott Williams and Wilkins
Year
2014
Tongue
English
Weight
44 KB
Volume
191
Category
Article
ISSN
0022-5347

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prostate cancer and PSA among statin use
Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial
✍ Teemu J. Murtola; Teuvo L.J. Tammela; Liisa Määttänen; Heini Huhtala; Elizabeth 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 177 KB 👁 1 views

## Abstract Decreased risk of advanced prostate cancer has been reported among men using statins. However, the evidence on overall prostate cancer risk is conflicting. We compared the relative risk between current users and non‐users of statins or other cholesterol‐lowering medications in a populat

Biological aggressiveness of prostate ca
Biological aggressiveness of prostate cancer in the Finnish screening trial
✍ Marita Laurila; Teuvo L.J. Tammela; Anssi Auvinen; Jorma Isola; Tapio Visakorpi; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 184 KB 👁 1 views

## Abstract Prostate cancer aggressiveness was evaluated based on pathologic characterization of cases detected in the Finnish prostate cancer screening trial. The trial population consists of 80,458 men aged 55–67 years. A total of 32,000 men were randomized to the screening arm. The remaining 48,

Test sensitivity of prostate-specific an
Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial
✍ Anssi Auvinen; Liisa Määttänen; Patrik Finne; Ulf-Håkan Stenman; Jussi Aro; Harr 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 77 KB 👁 1 views

## Abstract We estimated the sensitivity of serum prostate‐specific antigen (PSA) as a screening test for prostate cancer in the Finnish randomised, population‐based prostate cancer screening trial. The study population consisted of 80,458 men aged 55–67 years identified from the national populatio